down arrow

Relmada Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US75955J4022
USD
4.00
-0.04 (-0.99%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.834.07

52 Week

0.245.12
Valuation
Technical
Day's Volume

CASH

878.54 k

Shareholding (Jun 2025)

FII

7.19%

Held by 35 FIIs

DII

82.9%

Held by 11 DIIs

Promoter

0.00%

How big is Relmada Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Relmada Therapeutics, Inc. has a market capitalization of 23.37 million, with net sales of 0.00 million and a net profit of -75.72 million over the latest four quarters. Shareholder's funds are at 35.52 million, and total assets are 45.82 million.

As of Jun 18, Relmada Therapeutics, Inc. has a market capitalization of 23.37 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -75.72 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 35.52 million and Total Assets at 45.82 million.

Read More

What does Relmada Therapeutics, Inc. do?

22-Jun-2025

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for central nervous system disorders, with a market cap of $23.37 million and a recent net profit of -$18 million. The company is classified as a micro-cap and has no dividend yield.

Overview:<BR>Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for central nervous system (CNS) disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -18 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 23.37 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.21<BR>Return on Equity: -337.88%<BR>Price to Book: 1.04<BR><BR>Contact Details:<BR>Address: 880 3rd Ave Fl 12, NEW YORK NY: 10022-4730<BR>Tel: ['1 646 8763459', '1 646 8763459']<BR>Website: https://www.relmada.com/

Read More

Who are in the management team of Relmada Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Relmada Therapeutics, Inc. includes Independent Chairman Charles Casamento, CEO Sergio Traversa, and Independent Directors John Glasspool, Paul Kelly, and Eric Schmidt, who collectively guide the company's strategic direction and operations.

As of March 2022, the management team of Relmada Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Charles Casamento, who serves as the Independent Chairman of the Board.<BR>- Mr. Sergio Traversa, who is the Chief Executive Officer and a Director.<BR>- Mr. John Glasspool, who is an Independent Director.<BR>- Mr. Paul Kelly, who is also an Independent Director.<BR>- Dr. Eric Schmidt, who serves as an Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is Relmada Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Relmada Therapeutics shows a mildly bullish trend with strong recent performance, but caution is advised due to mixed signals, including a bearish weekly RSI and concerning long-term returns.

As of 3 September 2025, the technical trend for Relmada Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish daily moving average. However, the weekly RSI remains bearish, indicating some caution. The stock has shown strong performance over the past month with a return of 148.49%, significantly outperforming the S&P 500's 2.33% return. Despite this, the longer-term returns are concerning, with a 1-year return of -52.72% compared to the S&P 500's 17.14%. Overall, while there are bullish indicators, the mixed signals suggest a cautious approach.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 53 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.29

stock-summary
Return on Equity

-426.05%

stock-summary
Price to Book

3.33

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-10 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
172.11%
0%
172.11%
6 Months
473.64%
0%
473.64%
1 Year
44.4%
0%
44.4%
2 Years
59.36%
0%
59.36%
3 Years
-13.04%
0%
-13.04%
4 Years
-76.37%
0%
-76.37%
5 Years
-88.54%
0%
-88.54%

Relmada Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Relmada Therapeutics, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Relmada Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish daily moving average. However, the weekly RSI remains bearish, indicating some caution. The stock has shown strong performance over the past month with a return of 148.49%, significantly outperforming the S&P 500's 2.33% return. Despite this, the longer-term returns are concerning, with a 1-year return of -52.72% compared to the S&P 500's 17.14%. Overall, while there are bullish indicators, the mixed signals suggest a cautious approach....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-182.61%
EBIT to Interest (avg)
-97.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.21
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
45.72%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.23
EV to EBIT
-0.01
EV to EBITDA
-0.01
EV to Capital Employed
-0.14
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-337.88%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 13 Schemes (9.91%)

Foreign Institutions

Held by 35 Foreign Institutions (7.19%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 44.38% vs 29.64% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.20",
          "val2": "-18.80",
          "chgp": "45.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.90",
          "val2": "-17.80",
          "chgp": "44.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 19.03% vs 37.07% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-83.90",
          "val2": "-103.70",
          "chgp": "19.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "3.80",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-80.00",
          "val2": "-98.80",
          "chgp": "19.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-10.20
-18.80
45.74%
Interest
0.00
0.00
Exceptional Items
-0.00
-0.00
Consolidate Net Profit
-9.90
-17.80
44.38%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 44.38% vs 29.64% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-83.90
-103.70
19.09%
Interest
0.00
0.00
Exceptional Items
0.00
3.80
-100.00%
Consolidate Net Profit
-80.00
-98.80
19.03%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 19.03% vs 37.07% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Relmada Therapeutics, Inc. stock-summary
stock-summary
Relmada Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for central nervous system (CNS) disorders. Its product candidate includes dextromethadone (d-methadone), REL-1017, REL-1015 (LevoCap ER), REL-1028 (BuTab) and REL-1021 (MepiGel). d-methadone (dextromethadone, REL-1017) is an N-methyl-D-aspartate (NMDA) receptor antagonist. d-methadone is a new chemical entity (NCE) that is being developed for the treatment of central nervous system (CNS) diseases and other disorders. It is also being developed for the treatment of depression, ophthalmological disorders and/or other potential indications. REL-1015 (LevoCap ER) product candidate is an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol. REL-1028 is a novel oral formulations of modified release buprenorphine. MepiGel is a topical dosage form of the local anesthetic mepivacaine.
Company Coordinates stock-summary
Company Details
880 3rd Ave Fl 12 , NEW YORK NY : 10022-4730
stock-summary
Tel: 1 646 87634591 646 8763459
stock-summary
https://www.relmada.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."